The effectiveness and safety of SARMs (Selective Androgen Receptor Modulators) remain a subject of uncertainty and debate. It’s challenging to definitively determine what may happen when using various SARMs, peptides, and GH-secretagogues marketed for “research purposes.” Consequently, it is advisable to exercise caution and avoid their use.
A recent case report study shed some light on the effects experienced by an individual who self-administered a SARM (LGD-4033) and a GH-secretagogue (MK-677). Contrary to claims that these compounds offer benefits without drawbacks, this individual encountered adverse changes in blood lipids and bone mineral density while also experiencing suppressed endogenous testosterone production.
While this individual did gain some lean body mass, a notable aspect was the concurrent gain in fat mass, which is not typically associated with the use of exogenous androgens or growth hormone. An intriguing observation was the decrease in bone mineral density, which is unusual since androgens usually increase it, and previous data did not suggest such an effect from MK-677. The exact cause of this decrease remains uncertain, but the authors speculate that the decline in endogenous testosterone may have played a role. It’s important to note that there was no analytical confirmation of the substances used by this individual, making it challenging to draw definitive conclusions.
In summary, while a single case report offers limited evidence, it suggests that the specific SARM product and GH-secretagogue used in this instance were effective in increasing lean mass and strength. However, these positive effects were accompanied by several unwanted side effects, including adverse changes in cholesterol levels, fat gain, and decreased bone mineral density. Therefore, individuals should exercise caution and consider the potential risks associated with the use of these compounds.
